Neurology Grand Rounds: Dr Jeff Cummings

Visiting Professor Series: Dr Jeff Cummings

Speaker: Jeff Cummings MD ScD
University of Nevada Las Vegas (UNLV)
Joy Chambers-Grundy Professor of Brain Science
Chair, Chambers-Grundy Center for Transformative Neuroscience
Department of Brain Health, School of Allied Health Sciences
Clinical Professor of Neurology, UNLV School of Medicine
University of Exeter
Professor of Neurology, College of Medicine and Health
CNS Innovations
Chief Scientific Advisor

Dr. Cummings is a leading clinical trialist and Alzheimer’s disease expert.  He founded the UCLA Alzheimer’s Disease Research Center and the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.  He is Research Professor at University of Nevada Las Vegas and Director of the Chambers-Grundy Center for Transformative Neuroscience. 

Topic: The Alzheimer’s drug development pipeline:  what’s coming for the treatment of Alzheimer patients?

The participant will understand:
1. The three major phases of drug development  
2. The major classes of drugs currently in development for Alzheimer’s disease 
3. The role of biomarkers in drug development

Dr. Cummings will describe the drugs in development for Alzheimer’s disease.  He will discuss the major trends in Alzheimer’s drug development including the impact of the recent approval in the US of aducanumab.  He will note the key role played by biomarkers in drug development.

These rounds are generously supported by Mrs. Alix and Mr. Jim Arnett and through formal partnership with the Division of Neurology by Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Grifols, Novartis, Paladin, Roche, Sanofi Genzyme, Sunovion, Teva and UCB.